Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the ...

FP West: Energy Insider: Go behind the oilpatch's closed doors in our new subscriber-exclusive newsletter. Suspension of ...

Data center power demand is projected to grow by 160% by 2030, creating unprecedented opportunities for energy infrastructure ...

Evommune, Inc. (NYSE: EVMN) (the "Company"), a clinical-stage biotechnology company developing innovative therapies that ...

Invent showed how agentic AI transforms software development with autonomous planning, vertical integration, and ...

Utilities that provide natural gas to customers are investing in smart technologies to modernize their infrastructure. These ...

The DX-H1 V-NPU has been honored with a CES 2026 Innovation Award, reinforcing the value of DEEPX's vision of "Edge AI as the ...

CBP casts the proposal as a routine update but the changes will create a biometric-verified, device-linked analytical ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...

Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 ...